The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer
Open accessAbstract
Tamoxifen is the most commonly used endocrine therapy for patients with hormone receptor (HR)-positive breast cancer. Despite its initial therapeutic efficacy, many patients eventually develop drug resistance, which remains a serious clinical challenge. To investigate roles of circular RNAs (circRNAs) in tamoxifen resistance, a tamoxifen-resistant MCF-7 cell line was established and screened for its circRNA expression profile by RNA sequencing. hsa_circ_0025202, a circRNA that was significantly downregulated, was selected for further investigation. Using a large cohort of clinical specimens, we found that hsa_circ_0025202 exhibited low expression in cancer tissues and was negatively correlated with lymphatic metastasis and histological grade. Gain- and loss-of-function assays indicated that hsa_circ_0025202 could inhibit cell proliferation, colony formation, and migration and increase cell apoptosis and sensitivity to tamoxifen. Bioinformatics and luciferase reporter assays verified that hsa_circ_0025202 could act as a miRNA sponge for miR-182-5p and further regulate the expression and activity of FOXO3a. Functional studies revealed that tumor inhibition and tamoxifen sensitization effects of hsa_circ_0025202 were achieved via the miR-182-5p/FOXO3a axis. Moreover, in vivo experiments confirmed that hsa_circ_0025202 could suppress tumor growth and enhance tamoxifen efficacy. Taken together, hsa_circ_0025202 served an anti-oncogenic role in HR-positive breast cancer, and it could be exploited as a novel marker for tamoxifen-resistant breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7
Zeng, K., Chen, X., Xu, M., Liu, X., Hu, X., Xu, T., Sun, H., Pan, Y., He, B., & Wang, S. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0454-8 · Cited by 628
RetractedcircRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family
Chen, L., Zhang, S., Wu, J., Cui, J., Zhong, L., Zeng, L., & Ge, S. (2017) · Oncogene · doi:10.1038/onc.2017.89 · Cited by 392
RetractedCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Circular RNAs are a large class of animal RNAs with regulatory potency
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S. D., Gregersen, L. H., Munschauer, M., et al. (2013) · Nature · doi:10.1038/nature11928 · Cited by 7,990
Natural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
DEGseq: an R package for identifying differentially expressed genes from RNA-seq data
Wang, L., Feng, Z., Wang, X., Wang, X., & Zhang, X. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp612 · Cited by 4,553
Self-citationSanger, H. L., Klotz, G., Riesner, D., Gross, H. J., & Kleinschmidt, A. K. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3852 · Cited by 2,296
Complementary Sequence-Mediated Exon Circularization
Zhang, X.-O., Wang, H.-B., Zhang, Y., Lu, X., Chen, L.-L., & Yang, L. (2014) · Cell · doi:10.1016/j.cell.2014.09.001 · Cited by 1,999
Regulation of circRNA biogenesis
Chen, L.-L., & Yang, L. (2015) · RNA Biology · doi:10.1080/15476286.2015.1020271 · Cited by 1,953
Cell-Type Specific Features of Circular RNA Expression
Salzman, J., Chen, R. E., Olsen, M. N., Wang, P. L., & Brown, P. O. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003777 · Cited by 1,950
CircRNA: functions and properties of a novel potential biomarker for cancer
Meng, S., Zhou, H., Feng, Z., Xu, Z., Tang, Y., Li, P., & Wu, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0663-2 · Cited by 1,521
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Circular RNAs in cancer: opportunities and challenges in the field
Kristensen, L. S., Hansen, T. B., Venø, M. T., & Kjems, J. (2018) · Oncogene · doi:10.1038/onc.2017.361 · Cited by 1,326
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Han, D., Li, J., Wang, H., Su, X., Hou, J., Gu, Y., Qian, C., Lin, Y., Liu, X., Huang, M., et al. (2017) · Hepatology · doi:10.1002/hep.29270 · Cited by 1,214
Self-citationCircular RNA Expression: Its Potential Regulation and Function
Salzman, J. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.03.002 · Cited by 804
Circular RNA and its mechanisms in disease: From the bench to the clinic
Han, B., Chao, J., & Yao, H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.010 · Cited by 788
Chen, J., Li, Y., Zheng, Q., Bao, C., He, J., Chen, B., Lyu, D., Zheng, B., Xu, Y., Long, Z., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.006 · Cited by 686
Self-citationDetecting circular RNAs: bioinformatic and experimental challenges
Szabo, L., & Salzman, J. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.114 · Cited by 683
Zhang, J., Liu, H., Hou, L., Wang, G., Zhang, R., Huang, Y., Chen, X., & Zhu, J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0719-3 · Cited by 517
Weng, W., Wei, Q., Toden, S., Yoshida, K., Nagasaka, T., Fujiwara, T., Cai, S., Qin, H., Ma, Y., & Goel, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2541 · Cited by 510
Critical role of FOXO3a in carcinogenesis
Liu, Y., Ao, X., Ding, W., Ponnusamy, M., Wu, W., Hao, X., Yu, W., Wang, Y., Li, P., & Wang, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0856-3 · Cited by 507
Self-citationArpino, G., Weiss, H., Lee, A. V., Schiff, R., De Placido, S., Osborne, C. K., & Elledge, R. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji249 · Cited by 484
Zhong, Z., Huang, M., Lv, M., He, Y., Duan, C., Zhang, L., & Chen, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.027 · Cited by 449
LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
Xue, X., Yang, Y. A., Zhang, A., Fong, K.-W., Kim, J., Song, B., Li, S., Zhao, J. C., & Yu, J. (2016) · Oncogene · doi:10.1038/onc.2015.340 · Cited by 432
circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a
He, R., Liu, P., Xie, X., Zhou, Y., Liao, Q., Xiong, W., Li, X., Li, G., Zeng, Z., & Tang, H. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0614-1 · Cited by 347
A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy
Du, W. W., Yang, W., Li, X., Awan, F. M., Yang, Z., Fang, L., Lyu, J., Li, F., Peng, C., Krylov, S. N., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0369-y · Cited by 335
Zhao, Y., Alexandrov, P., Jaber, V., & Lukiw, W. (2016) · Genes · doi:10.3390/genes7120116 · Cited by 321
Chen, G., Shi, Y., Liu, M., & Sun, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0204-3 · Cited by 294
circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression
Chen, B., Wei, W., Huang, X., Xie, X., Kong, Y., Dai, D., Yang, L., Wang, J., Tang, H., & Xie, X. (2018) · Theranostics · doi:10.7150/thno.24106 · Cited by 281
Self-citationWard, A., Balwierz, A., Zhang, J. D., Küblbeck, M., Pawitan, Y., Hielscher, T., Wiemann, S., & Sahin, Ö. (2013) · Oncogene · doi:10.1038/onc.2012.128 · Cited by 280
Li, R.-C., Ke, S., Meng, F.-K., Lu, J., Zou, X.-J., He, Z.-G., Wang, W.-F., & Fang, M.-H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0852-y · Cited by 203
Estrogen receptor: current understanding of its activation and modulation.
Osborne, C. K., Schiff, R., Fuqua, S. A. W., & Shou, J. (2001) · PubMed · Cited by 194
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Cittelly, D. M., Das, P. M., Spoelstra, N. S., Edgerton, S. M., Richer, J. K., Thor, A. D., & Jones, F. E. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-317 · Cited by 191
Broadbent, K. M., Broadbent, J. C., Ribacke, U., Wirth, D., Rinn, J. L., & Sabeti, P. C. (2015) · BMC Genomics · doi:10.1186/s12864-015-1603-4 · Cited by 179
Li, Y., Liang, Y., Sang, Y., Song, X., Zhang, H., Liu, Y., Jiang, L., & Yang, Q. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0030-7 · Cited by 179
Self-citationCircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis
Wu, J., Jiang, Z., Chen, C., Hu, Q., Fu, Z., Chen, J., Wang, Z., Wang, Q., Li, A., Marks, J. R., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.033 · Cited by 164
Zou, Y., Tsai, W.-B., Cheng, C.-J., Hsu, C., Chung, Y. M., Li, P.-C., Lin, S.-H., & Hu, M. C. ‐. (2008) · Breast Cancer Research · doi:10.1186/bcr1872 · Cited by 158
Endocrine treatment in breast cancer: Cure, resistance and beyond
Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 153
Su, C., Han, Y., Zhang, H., Li, Y., Yi, L., Wang, X., Zhou, S., Yu, D., Song, X., Xiao, N., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13587 · Cited by 127
Self-citationMicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway
Liang, Z. C., Wang, X., Xu, X., Xie, B., Ji, A., Meng, S., Li, S., Zhu, Y., Wu, J., Hu, Z., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0664-1 · Cited by 98
Ahmad, A., Ginnebaugh, K. R., Yin, S., Bollig-Fischer, A. B., Reddy, K. B., & Sarkar, F. H. (2015) · BMC Cancer · doi:10.1186/s12885-015-1561-x · Cited by 81
Dai, X., Zhang, N., Cheng, Y., Yang, T., Chen, Y. P., Liu, Z., Wang, Z., Yang, C., & Jiang, Y. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy061 · Cited by 79
Self-citationFu, G., & Peng, C. (2011) · Oncogene · doi:10.1038/onc.2011.127 · Cited by 69
Ojo, D., Wei, F., Liu, Y., Wang, E., Zhang, H., Lin, X., Wong, N., Bane, A. L., & Tang, D. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150416095744 · Cited by 62
Self-citationJiang, Q., Zheng, S., & Wang, G. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.63 · Cited by 49
Anandasadagopan, S. K., Mohebali, N., Looi, C. Y., Hasanpourghadi, M., Pandurangan, A. K., Arya, A., Karimian, H., & Mustafa, M. R. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0266-y · Cited by 49
Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance
Raha, P., Thomas, S., & Münster, P. N. (2011) · Epigenomics · doi:10.2217/epi.11.72 · Cited by 38
Gao, S., Li, X., Ding, X., Jiang, L., & Yang, Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-07550-9 · Cited by 33
Self-citation
Cited by
The emerging roles of circRNAs in cancer and oncology
Kristensen, L. S., Jakobsen, T., Hager, H., & Kjems, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00585-y · Cited by 1,256
Targeting circular RNAs as a therapeutic approach: current strategies and challenges
He, A. T., Liu, J., Li, F., & Yang, B. B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00569-5 · Cited by 549
CircRNA inhibits DNA damage repair by interacting with host gene
Xu, X., Zhang, J., Tian, Y., Gao, Y., Dong, X., Chen, W., Yuan, X., Yin, W., Xu, J., Chen, K., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01246-x · Cited by 366
Roles of circRNAs in the tumour microenvironment
Zhang, Q., Wang, W., Zhou, Q., Chen, C., Yuan, W., Liu, J., Li, X., & Sun, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1125-9 · Cited by 260
The emerging regulatory roles of non-coding RNAs associated with glucose metabolism in breast cancer
Kansara, S., Singh, A., Badal, A. K., Rani, R., Baligar, P., Garg, M., & Pandey, A. K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.06.007 · Cited by 32
Metadata
- Authors
- Sang, Y., Chen, B., Song, X., Li, Y., Liang, Y., Han, D., Zhang, N., Zhang, H., Liu, Y., Chen, T., Li, C., Wang, L., Zhao, W., & Yang, Q.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 27
- Issue
- 9
- Pages
- 1638-1652
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2945838677
- Cited by
- 460
- References
- 52
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.